doi: 10.3389/fneur.2024.1413023 Received 06 April 2024 Accepted 18 July 2024 Published 14 August 2024 Volume 15 - 2024 Edited by Dinesh Upadhya, Manipal Academy of Higher Education, India Reviewed by Aastha Dheer, Mayo Clinic, United States Pablo Bascuana, San Carlos University Clinical Hospital, Spain Updates Copyright 2024 Han, Wang, Wei, Lu and Shan
Enter your email to reset your password.
The molecular cavity detection algorithm within Make Receptor was then used to define the active site shape and size, which was determined to have a volume of 1378 3
[4] Therefore, in initiating or continuing treatment with dutasteride, clinicians should weigh the known benefits of treatment against the potential risk and be aware that dutasteride may increase the risk of high-grade prostate cancer